GLP-1 (S) serves as the baseline reference in comparative incretin research. By targeting only the GLP-1 receptor, it allows researchers to isolate GLP-1-specific effects from those produced by GIP or glucagon receptor co-activation. Published research on semaglutide-class compounds has established their effects on insulin secretion, appetite regulation, and gastric emptying in extensive clinical trials.1
METABOLIC
GLP – 1 (S)
$64.99
GLP – 1 (S) is a synthetic GLP-1 receptor agonist peptide developed for the investigation of glucose regulation, insulin signaling, and appetite pathways. It is structurally modified to resist enzymatic degradation and prolong half-life. GLP – 1 (S) is supplied for controlled laboratory research and is not intended for human or veterinary use.
Quantity5mg
FormulaC187H291N45O59
Mol. Weight~4113.58 g/mol
PuritySee COA
Free shipping on orders over $200
Download Certificate of AnalysisAbout This Compound
Product Overview
GLP-1 (S) is OSYRIS Health's designation for a single GLP-1 receptor agonist in the semaglutide class. Unlike the dual agonist GLP-2 (T) or the triple agonist GLP-3 (R), GLP-1 (S) targets only the GLP-1 receptor — providing researchers with a clean pharmacological tool for studying GLP-1-specific effects without the confounding variables introduced by additional receptor activation.
The GLP-1 receptor is expressed in the pancreas, brain, heart, and gastrointestinal tract. Its activation produces a range of metabolic effects that have been extensively documented in preclinical and clinical research, making GLP-1 receptor agonism one of the most studied pharmacological approaches in metabolic research. GLP-1 (S) has a molecular weight of 4113.58 g/mol and is supplied as a lyophilized powder.
Research Applications
Mechanism and Experimental Context
GLP-1 receptor activation in the hypothalamus and brainstem modulates appetite through multiple mechanisms: delayed gastric emptying (food stays in the stomach longer, prolonging satiety), direct hypothalamic appetite suppression, and altered reward-based eating behavior. GLP-1 (S) is used in preclinical models to study these mechanisms in isolation from other receptor systems.2
The primary research value of GLP-1 (S) is in comparison with OSYRIS GLP-2 (T) and GLP-3 (R). By testing all three — single, dual, and triple agonist — researchers can determine the incremental contribution of each additional receptor target. This comparative approach is fundamental to understanding incretin pharmacology.3
Explore Related Compounds
Keep the Research Trail Moving
Referenced Studies
Source Literature
[1]
Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine, 2021. PubMed: PMID 33567185
[2]
van Can J, et al. "Reduced GLP-1 responses after meal intake in obese subjects." Diabetes Research and Clinical Practice, 2014.
[3]
Nauck MA, Meier JJ. "Incretin hormones: their role in health and disease." Diabetes, Obesity and Metabolism, 2018. PubMed: PMID 29364588
Certificate of Analysis
Batch Documentation
Current published batch documentation is surfaced on-page whenever the provider exposes a public COA asset.
Frequently Asked Questions
Questions About GLP – 1 (S)
GLP-1 (S) is OSYRIS's designation for a single GLP-1 receptor agonist in the semaglutide class. It targets only the GLP-1 receptor, making it useful for studying GLP-1-specific biology.
GLP-1 (S) targets one receptor, GLP-2 (T) targets two, and GLP-3 (R) targets three. Researchers use all three to determine what each additional receptor target contributes to overall metabolic effects.
Semaglutide (Ozempic, Wegovy, Rybelsus) is FDA-approved as a prescription medication. OSYRIS GLP-1 (S) is a research-grade compound sold exclusively for laboratory research. It is not a pharmaceutical product.
Glucagon-Like Peptide 1. It's an incretin hormone naturally produced in the gut after eating. It stimulates insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite.
Store at -20°C for long-term or 2-8°C for short-term. Protect from light.
Independently tested via HPLC and LC-MS. COA downloadable on this page.
GLP-1 agonism is one of the most extensively studied approaches in metabolic research, with a large clinical evidence base. Understanding GLP-1-specific effects is foundational to incretin pharmacology.
4113.58 g/mol (C₁₈₇H₂₉₁N₄₅O₅₉).
Every Batch Tested by an Independent Lab
We publish the Certificate of Analysis for every product. See our full testing process.